Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Durvalumab (Imfinzi) is indicated for the treatment of adult patients with various types of lung cancer and biliary tract cancer, as well as unresectable hepatocellular carcinoma. It can be used alone or in combination with other drugs such as etoposide, carboplatin, cisplatin, tremelimumab-actl, and gemcitabine.
• A total of 20 studies were reviewed to gather information about durvalumab's effectiveness and safety compared to other therapeutic options like nivolumab, pembrolizumab, atezolizumab, and immune checkpoint inhibitors combined with chemotherapies.
• In terms of hepatocellular carcinoma (HCC) with PVTT treatment outcomes, HAIC-FO combined with sorafenib showed more favorable results than combinations involving durvalumab.
• For Stage III Unresectable NSCLC patients who have undergone concurrent platinum-based chemotherapy and radiation therapy without disease progression, post-treatment use of durvalumab is associated with significant improvement in 1-year overall survival rates (OS) and progression-free survival rates (PFS).
• When treating extensive-stage small cell lung cancer (ES-SCLC), although effective when used alongside chemotherapy, durvalumab was found less beneficial than serplulimab regarding OS & PFS benefits, positioning it as a viable but not the most effective option within this indication.
• Durvalumab has shown promising potential when paired with gemcitabine for advanced BTC treatments by offering a balance between tolerability and enhanced survival outcomes.
• In real-world scenarios involving the stage III NSCLC patient population, durvalumab demonstrated similar safety and efficacy profiles to those observed during clinical trials, despite the inclusion of a broader patient population, thus highlighting its practical applicability.
• The incidence of adverse events across indications, especially among elderly patients or those with compromised performance status, emphasizes the importance of monitoring and managing potential toxicities while using the drug.